![]() |
市場調査レポート
商品コード
1679220
医療用ポリマーの2030年までの市場予測:製品タイプ、製造プロセス、用途、地域別の世界分析Medical Polymers Market Forecasts to 2030 - Global Analysis By Product Type (Biodegradable Polymers and Non-Biodegradable Polymers), Manufacturing Process, Application and By Geography |
||||||
カスタマイズ可能
|
医療用ポリマーの2030年までの市場予測:製品タイプ、製造プロセス、用途、地域別の世界分析 |
出版日: 2025年03月03日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2~3営業日
|
Stratistics MRCによると、世界の医療用ポリマー市場は2024年に413億米ドルを占め、予測期間中のCAGRは8.7%で成長し、2030年には682億米ドルに達する見込みです。
医療用ポリマーは、ドラッグデリバリーシステム、包装、インプラント、医療機器に利用される特殊材料です。これらのポリマーは耐久性、柔軟性、生体適合性を提供します。シリコーン、ポリエチレン、ポリプロピレン、生分解性などがあります。手術器具、人工器官、カテーテル、医薬品包装の製造に不可欠です。軽量設計、耐薬品性、滅菌性により、患者の安全性、有効性、様々な医療用途でのより良い結果を保証するため、現代医療にとって極めて重要です。
PMCの調査によると、米国は世界で製造される医療機器の約40%を消費しており、次いで欧州、日本となっています。
医療機器とインプラントに対する需要の高まり
慢性疾患の増加と高齢化が、医療機器・インプラント分野の大幅な成長を促しています。高度な医療用具、器具、インプラントに対する需要の急増が、医療用ポリマー市場を直接後押ししています。高度なポリマー技術により、生体適合性、弾力性、医療環境での簡単な滅菌手順を保証する最先端の医療器具の作成が可能になり、現代のヘルスケア提供に不可欠なものとなっています。
原材料費の高騰
医療用ポリマーの製造コストの高騰は、市場の成長にとって大きな課題となります。製造工程には特殊な設備、熟練した労働力、多大なエネルギー投入が必要である一方、原材料は希少で高価な場合が多いです。製造コストは従来のポリマーの最大5倍にもなるため、多くの用途では経済的に困難であり、コストに敏感な分野での普及には限界があります。
ドラッグデリバリーへの応用拡大
バイオ医薬品と個別化医療の成長により、ポリマーベースのドラッグデリバリーシステムに大きな機会が生まれています。高度なポリマー製剤は、薬剤の制御された長時間放出を可能にし、治療効果と患者のアドヒアランスを高めます。3Dプリンティングやナノテクノロジーなどの新技術の統合により、薬剤製剤の精度とカスタマイズ性が向上し、研究開発への投資が促進されています。
製造物責任とリコールのリスク
医療機器は、当初の設計を変更したり補足したりすることで、リコールのリスクが約30%高まります。ポリマーをベースとする医療機器は複雑であり、規制要件も厳しいため、重大な賠償責任リスクが生じます。ある種のポリマーと健康への悪影響を関連づけた最近の研究によって安全性への懸念が高まり、市場の成長に影響を与える可能性があるほか、メーカーは厳格な品質管理対策を維持する必要があります。
COVID-19の大流行は、主に予防接種用の使い捨て注射器の需要増によって、医療用ポリマー市場にプラスの影響を与えました。製薬業界の繁栄は、医薬品包装への要求の高まりを通じて市場成長に大きく貢献しました。世界の感染症の脅威は、ヘルスケア用途における医療用ポリマーの重要性を浮き彫りにし、市場の拡大を加速させました。
予測期間中、非生分解性ポリマー分野が最大になる見込み
非生分解性ポリマーセグメントは、優れた耐久性、耐薬品性、確立された製造プロセスにより、予測期間中最大の市場シェアを占めると予想されます。これらの材料は、長期の医療機器、手術用器具、医療用包装用途に広く使用されています。その信頼性は、重要な医療用途で実証された性能と相まって、ヘルスケアプロバイダーや医療機器メーカーに好まれる選択肢となっており、市場の主導権を確保し続けています。
組織工学・再生医療分野は予測期間中に最も高いCAGRが見込まれる
予測期間中、技術的進歩とバイオテクノロジーへの投資の増加により、組織工学・再生医療分野が最も高い成長率を示すと予測されます。組織再生のための革新的なポリマーベースの足場やマトリックスの開発により、再生医療に新たな可能性が生まれています。このセグメントの拡大は、研究活動の活発化と高度な治癒ソリューションに対する需要の高まりによってさらに支えられています。
予測期間中、北米地域は、広範なヘルスケアインフラと先進医療技術の高い導入率に牽引され、最大の市場シェアを占めると予想されます。この地域の優位性は、医療へのアクセスを拡大し、医療機器や医薬品包装の需要を増加させた医療費負担適正化法やメディケイドのような政府の重要なイニシアチブによって強化されています。
予測期間中、アジア太平洋地域は急速なヘルスケアセクターの拡大と医療ツーリズムの増加により、最も高いCAGRを示すと予測されます。タイ、シンガポール、インドなどの国々が主要な医療観光地として台頭しており、洗練された医療機器やインプラントの需要に拍車をかけています。この地域の成長は、政府のイニシアティブとヘルスケア支出の増加によってさらに支えられています。
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
According to Stratistics MRC, the Global Medical Polymers Market is accounted for $41.3 billion in 2024 and is expected to reach $68.2 billion by 2030 growing at a CAGR of 8.7% during the forecast period. Medical polymers are specialty materials utilized in drug delivery systems, packaging, implants, and medical equipment. These polymers provide durability, flexibility, and biocompatibility. They include silicone, polyethylene, polypropylene, and biodegradable varieties. They are essential to the production of surgical equipment, prosthesis, catheters, and pharmaceutical packaging. They are crucial to modern medicine because of their lightweight design, chemical resistance, and sterilizability, which guarantee patient safety, effectiveness, and better results in a range of medical applications.
According to PMC studies, the US consumes around 40% of medical devices manufactured globally, followed by Europe and Japan.
Rising demand for medical devices and implants
The increasing prevalence of chronic diseases and aging population is driving substantial growth in the medical devices and implants sector. The surge in demand for sophisticated medical tools, apparatus, and implants has directly boosted the medical polymers market. Advanced polymer technology has enabled the creation of cutting-edge medical devices that ensure biocompatibility, resilience, and straightforward sterilization procedures in medical environments, making them essential for modern healthcare delivery.
High cost of raw materials
The elevated production costs of medical polymers pose significant challenges to market growth. The manufacturing processes require specialized equipment, skilled labor, and considerable energy input, while raw materials are often rare and expensive. The production costs can be up to five times higher than conventional polymers, making them economically challenging for many applications and limiting widespread adoption across cost-sensitive sectors.
Expanding applications in drug delivery
The growth in biopharmaceuticals and personalized medicine has created significant opportunities for polymer-based drug delivery systems. Advanced polymeric formulations enable controlled and prolonged release of medications, enhancing treatment efficacy and patient adherence. The integration of novel technologies like 3D printing and nanotechnology is improving the precision and customization of drug formulations, driving investment in research and development.
Product liability and recall risks
Medical devices face approximately 30% increased risk of recalls following modifications and supplements to their original design. The complexity of polymer-based medical devices and stringent regulatory requirements create significant liability risks. Recent studies linking certain polymers to adverse health effects have raised safety concerns, potentially impacting market growth and requiring manufacturers to maintain rigorous quality control measures.
The Covid-19 pandemic had a positive impact on the medical polymers market, primarily driven by increased demand for single-use syringes for vaccinations. The thriving pharmaceutical industry contributed significantly to market growth through elevated requirements for medication packaging. The global threat of infectious diseases highlighted the importance of medical polymers in healthcare applications, accelerating market expansion.
The non-biodegradable polymers segment is expected to be the largest during the forecast period
The non-biodegradable polymers segment is expected to account for the largest market share during the forecast period due to their superior durability, chemical resistance, and established manufacturing processes. These materials are extensively used in long-term medical devices, surgical instruments, and medical packaging applications. Their reliability, coupled with proven performance in critical medical applications, has made them the preferred choice for healthcare providers and medical device manufacturers, ensuring their continued market leadership.
The tissue engineering & regenerative medicine segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the tissue engineering & regenerative medicine segment is predicted to witness the highest growth rate due to technological advancements and increasing investment in biotechnology. The development of innovative polymer-based scaffolds and matrices for tissue regeneration has opened new possibilities in regenerative medicine. This segment's expansion is further supported by growing research activities and the rising demand for advanced healing solutions.
During the forecast period, the North America region is expected to hold the largest market share driven by extensive healthcare infrastructure and high adoption of advanced medical technologies. The region's dominance is reinforced by significant government initiatives like the Affordable Care Act and Medicaid, which have expanded healthcare access and increased demand for medical devices and pharmaceutical packaging.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rapid healthcare sector expansion and increasing medical tourism. Countries like Thailand, Singapore, and India are emerging as major medical tourism destinations, fueling demand for sophisticated medical devices and implants. The region's growth is further supported by government initiatives and increasing healthcare expenditure.
Key players in the market
Some of the key players in Medical Polymers Market include Medtronic PLC, Johnson & Johnson, DowDuPont, BASF SE, Evonik Industries AG, Covestro AG, Asahi Kasei Corporation, DSM, Mitsubishi Chemical Corporation, Lubrizol Corporation, SABIC, Solvay S.A., Arkema S.A., Celanese Corporation, Eastman Chemical Company, Kraton Corporation, Tekni-Plex, Inc. and Victrex plc.
In October 2024, The Japanese technology company Asahi Kasei signed a memorandum of understanding (MOU) with Aquafil S.p.A., an Italian manufacturer of polyamide 6 (PA6). The two companies agreed to develop a novel material for 3D printing (3DP) applications utilizing Aquafil's ECONYL(R) Polymer chemically recycled PA6 and Asahi Kasei's cellulose nanofiber (CNF), with the support of ITOCHU Corporation, which has made a capital investment in Aquafil. Pellets or filaments of this compound achieve superior formability and strength, which make them suitable for use in automotive and aeronautical applications.
In September 2024, Evonik has officially opened a new facility for drying aqueous dispersions of EUDRAGIT(R) polymers at its site in Darmstadt. The new double-digit million-euro excipient manufacturing facility enables Evonik to meet the increasing demand from pharmaceutical customers for oral drug delivery solutions. By expanding production capacities, Evonik is improving supply security and shortening delivery times for EUDRAGIT(R) polymers. The new plant also operates using green electricity and steam generated from local waste incineration, saving more than 1,000 tons of CO2 equivalents per year.
In October 2023, BASF changed its European direct business for Ultraform(R) (POM) and transfer the sales process to its long-standing trusted trading partners, ALBIS and Ultrapolymers Group. Ultraform(R) is and will remain an important part of BASF's engineering plastics portfolio. By maintaining research and development for Ultraform(R) within BASF, customers will continue to benefit from BASF's innovations and broad expertise, especially in solving technical challenges.